Author

Knut E.A. Lundin

IMMUNE RESPONSES TO COVID-19 VACCINES IN CELIAC DISEASE
IMMUNE RESPONSES TO COVID-19 VACCINES IN CELIAC DISEASE

Knut E.A. Lundin  et al.

GLUTEN-FREE DIET INVOKES INSTANT CHANGES IN PHENOTYPE AND SURVIVAL PROPERTIES OF GLUTEN-SPECIFIC T CELLS IN CELIAC DISEASE
GLUTEN-FREE DIET INVOKES INSTANT CHANGES IN PHENOTYPE AND SURVIVAL PROPERTIES OF GLUTEN-SPECIFIC T CELLS IN CELIAC DISEASE

Knut E.A. Lundin  et al.

SEROLOGICAL SIGNS OF COELIAC DISEASE IN PRE-DIAGNOSTIC SAMPLES FROM A POPULATION-BASED COHORT OF COELIACS, THE TRØNDELAG HEALTH STUDY (HUNT), NORWAY
SEROLOGICAL SIGNS OF COELIAC DISEASE IN PRE-DIAGNOSTIC SAMPLES FROM A POPULATION-BASED COHORT OF COELIACS, THE TRØNDELAG HEALTH STUDY (HUNT), NORWAY

Knut E.A. Lundin  et al.

ESsCD Guideline for coeliac disease and other gluten-related disorders
ESsCD Guideline for coeliac disease and other gluten-related disorders

Knut E.A. Lundin  et al.

THE DEVELOPMENT AND VALIDATION OF A HIGH-CAPACITY SEROLOGICAL ASSAY FOR COELIAC DISEASE
THE DEVELOPMENT AND VALIDATION OF A HIGH-CAPACITY SEROLOGICAL ASSAY FOR COELIAC DISEASE

Knut E.A. Lundin  et al.

THE PREVALENCE OF COELIAC DISEASE IN THE UNSELECTED GENERAL POPULATION
THE PREVALENCE OF COELIAC DISEASE IN THE UNSELECTED GENERAL POPULATION

Knut E.A. Lundin  et al.

SCREENING FOR ADULT COELIAC DISEASE IN THE GENERAL POPULATION
SCREENING FOR ADULT COELIAC DISEASE IN THE GENERAL POPULATION

Knut E.A. Lundin  et al.

DIAGNOSIS AND FOLLOW-UP OF CELIAC DISEASE – A CONTEMPORARY PATIENT MATERIAL
DIAGNOSIS AND FOLLOW-UP OF CELIAC DISEASE – A CONTEMPORARY PATIENT MATERIAL

Knut E.A. Lundin  et al.

SEROLOGIC RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNOSUPPRESSIVE THERAPY: ASSOCIATION TO DISEASE TYPE AND SERUM DRUG LEVELS
SEROLOGIC RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNOSUPPRESSIVE THERAPY: ASSOCIATION TO DISEASE TYPE AND SERUM DRUG LEVELS

Knut E.A. Lundin  et al.

TERIFLUNOMIDE AS IMMUNOTHERAPY FOR CELIAC DISEASE – RESULTS FROM A DOUBLE-BLINDED, RANDOMIZED PHASE 2A STUDY
TERIFLUNOMIDE AS IMMUNOTHERAPY FOR CELIAC DISEASE – RESULTS FROM A DOUBLE-BLINDED, RANDOMIZED PHASE 2A STUDY

Knut E.A. Lundin  et al.

Item 1 - 10 / 10
1